Authors: Koch, P del Valle, F Berdel, WE Willich, NA Reers, B Hiddemann, W Grothaus-Pinke, B Reinartz, G Brockmann, J Temmesfeld, A Schmitz, R Rube, C Probst, A Jaenke, G Bodenstein, H Junker, A Pott, C Schultze, J Heinecke, A Parwaresch, R Tiemann, M

Citation: P. Koch et al., Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92, J CL ONCOL, 19(18), 2001, pp. 3861-3873

Authors: Koch, P del Valle, F Berdel, WE Willich, NA Reers, B Hiddemann, W Grothaus-Pinke, B Reinartz, G Brockmann, J Temmesfeld, A Schmitz, R Rube, C Probst, A Jaenke, G Bodenstein, H Junker, A Pott, C Schultze, J Heinecke, A Parwaresch, R Tiemann, M

Citation: P. Koch et al., Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical andconservative or conservative management only in localized gastric lymphoma- Results of the Prospective German Multicenter Study GIT NHL 01/92, J CL ONCOL, 19(18), 2001, pp. 3874-3883

Authors: Wandt, H Frank, M Denzel, T Aulitzky, W Bodenstein, H Brack, N Duerk, H Engberding, R Fauser, A Geer, T Germann, B Gramatzki, M Kaesberger, J Kisro, J Knigge, O Kochling, G Kuse, R Link, H Neubauer, A Ohl, S Pfluger, R Saal, J Schakel, U Schalk, K Schmidt, H Soucek, S Wagner, T Wilms, K Winter, R Ehninger, G

Citation: H. Wandt et al., The 10.000/mu l morning trigger for prophylactic platelet transfusion is safe: Prospective experience in 411 AML patients, HEMAT BLOOD, 40, 2001, pp. 488-490

Authors: Vanhoefer, U Rougier, P Wilke, H Ducreux, MP Lacave, AJ Van Cutsem, E Planker, M Dos Santos, JG Piedbois, P Paillot, B Bodenstein, H Schmoll, HJ Bleiberg, H Nordlinger, B Couvreur, ML Baron, B Wils, JA

Citation: U. Vanhoefer et al., Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European organization for research and treatment of cancer gastrointestinal tract cancer cooperative group, J CL ONCOL, 18(14), 2000, pp. 2648-2657

Authors: Heidemann, E Stoeger, H Souchon, R Hirschmann, WD Bodenstein, H Oberhoff, C Fischer, JT Schulze, M Clemens, M Andreesen, R Mahlke, M Konig, M Scharl, A Gruener, A Fehnle, K Kaufmann, M

Citation: E. Heidemann et al., First-line chemotherapy for metastatic breast cancer in high-risk patients- Greater therapeutic effect with mitoxantron monotherapy than with combination therapy with 5-fluorouracil, epirubicin and cyclophosphamide, ONKOLOGIE, 23(3), 2000, pp. 2-4

Authors: Heidemann, E Souchon, R Stoger, H Hirschmann, WD Bodenstein, H Oberhoff, C Fischer, JT Schulze, M Clemens, M Mahlke, M Konig, M Scharl, A Fehnle, K Kaufmann, M

Citation: E. Heidemann et al., First-line monochemotherapy with mitoxantrone versus combination with fluorouracil, epirubicin and cyclophosphamide in high-risk metastatic breast cancer: A prospective randomized multicenter clinical trial, ONKOLOGIE, 23(1), 2000, pp. 54-59